fls.txt



item1.txt
See notes to unaudited condensed consolidated financial statements.
See notes to unaudited condensed consolidated financial statements.
See notes to unaudited condensed consolidated financial statements.
See notes to unaudited condensed consolidated financial statements.
The accompanying unaudited interim condensed consolidated financial statements are prepared pursuant to the Securities and Exchange Commission’s rules and regulations for reporting on Form 10-Q.
The Company believes all adjustments necessary for a fair presentation of these interim statements have been included and that they are of a normal and recurring nature.
The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary, and Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation and wholly-owned subsidiary, and Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary (all collectively referred to as the “Company”).
All material intercompany balances and transactions have been eliminated.
2016-02, Leases, which replaces previous lease guidance in its entirety with ASC 842 and requires lessees to recognize lease assets and lease liabilities for those arrangements classified as operating leases under previous guidance, with the exception of leases with a term of twelve months or less.
The Company records revenues in accordance with Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers, as amended” (“ASC Topic 606”).
Customers either pay by credit card (online sales) or net 30-90, depending on the customer.
The standard warranty is typically comprised of one to two years of parts and labor and is deemed immaterial.
Catalyst research instruments are never returned for repairs.
Approximately 33% and 25% of total Benchtop Laboratory Equipment sales were derived from the Torbal Scales Division for the three months ended September 30, 2019 and 2018, respectively.
For the three months ended September 30, 2019 and 2018, respectively, three customers accounted for approximately 23% (both periods) of net sales of the Benchtop Laboratory Equipment Operations (18% and 19% of the Company’s total revenues).
Fair value measurements do not include transaction costs.
Level 1 - Inputs that are based upon unadjusted quoted prices for identical instruments traded in active markets.


item2.txt
The Company reflected a loss before income tax expense of $75,700 for the three months ended September 30, 2019 compared to income before tax expense of $177,500 for the three months ended September 30, 2018, primarily from the result of decreased revenues and gross margins for the Benchtop Laboratory Equipment Operations resulting from reduced orders from Asia, primarily China, and increased component costs as a result of tariffs imposed.
Net revenues for the three months ended September 30, 2019 decreased $34,400 (1.7%) to $2,004,200 from $2,038,600 for the three months ended September 30, 2018, reflecting a decrease of $115,700 (6.8%) decrease in net sales of Benchtop Laboratory Equipment primarily due to sales of its Genie brand products to Asia, particularly China.
The Benchtop Laboratory Equipment sales reflected $522,400 of Torbal brand product sales for the three months ended September 30, 2019, compared to $425,300 in the three months ended September 30, 2018 as a result of continued growth in sales of the new force gauges product line.
Sales of Catalyst Research Instruments decreased by $78,800 to $138,700 for the three months ended September 30, 2019 compared to $217,500 for the three months ended September 30, 2018 due to low order input during the period.
As of September 30, 2019, the order backlog for Catalyst Research Instruments was $173,500, all of which is expected to be shipped during the fiscal year ending June 30, 2020, compared to $329,400 as of September 30, 2018.
Revenues derived from the Bioprocessing Systems Operations which are comprised primarily of net royalties accrued from sublicenses increased by $160,100 (123.9%) to $289,300 for the three months ended September 30, 2019 compared to $129,200 for the three months ended September 30, 2018 due to increased royalties on Europe sales.
General and administrative expenses for the three months ended September 30, 2019 increased by $93,700 (22.5%) to $510,200 compared to $416,500 for the three months ended September 30, 2018 mainly due to the ramp up in Scientific Bioprocessing Operations, and various other corporate expenses.
Selling expenses for the three months ended September 30, 2019 increased $73,000 (30.9%) to $309,100 from $236,100 for the three months ended September 30, 2018 primarily due to increased market research and marketing activities by the Bioprocessing Systems Operations, and to a lesser extent increased marketing by the Benchtop Laboratory Equipment Operations.
Research and development expenses increased by $119,200 (101.5%) to $236,600 for the three months ended September 30, 2019 compared to $117,400 for the three months ended September 30, 2018, mainly due to the ramp up in product development activities by the Bioprocessing Systems Operations which included staffing and materials.


